Trial Profile
6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naive Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Anti-hyperglycaemic Drugs With a 6-month Safety Extension Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EDITION-III
- Sponsors Sanofi
- 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 25 Sep 2020 Results of pooled analysis from NCT02855684; NCT01689142 and NCT01676220 assessing efficacy and safety of Gla-300 in East Asian population with type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 11 Jun 2019 Results reporting data on patient satisfaction from EDITION 3 and BRIGHT trial presented at the 79th Annual Scientific Sessions of the American Diabetes Association